CYP2C9 genetic variants and losartan oxidation in a Turkish population

Babaoglu, MO; Yasar, ÜMİT; Sandberg, M; Eliasson, E; Dahl, ML; Kayaalp, SO; Bozkurt, ATİLLA

doi:10.1007/s00228-004-0785-5

CYP2C9 genetic variants and losartan oxidation in a Turkish population

Babaoglu M., Yasar U., Sandberg M., Eliasson E., Dahl M., Kayaalp S., ...Daha Fazla

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.60, sa.5, ss.337-342, 2004 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 60 Sayı: 5
Basım Tarihi: 2004
Doi Numarası: 10.1007/s00228-004-0785-5
Dergi Adı: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.337-342
Hacettepe Üniversitesi Adresli: Evet

Özet

Objective. Cytochrome P-450 2C9 (CYP2C9) is a polymorphic enzyme catalysing the metabolism of several important drugs. Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity. The aim of the study was to determine the activity of CYP2C9, using losartan as a probe drug, in relation to CYP2C9 genotype in healthy Turkish subjects.